Bristol Myers Squibb (BMY) finished the most recent trading session at $60.28, which is an increase of 0.79% compared to the previous day.
Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Leerink Partners 2025 Global Healthcare Conference Call on March 12, 2025, at 11:20 AM ET. The call will feature Roland Chen, who is the Head of Development for Immunology, Cardiology, and Neuroscience. David Risinger from Leerink Partners will also be part of the discussion.
On March 11, 2025, Rowley Law PLLC announced that it is looking into possible violations of securities laws by 2seventy bio, Inc. and its board regarding the planned purchase of the company by Bristol Myers Squibb. Shareholders will get $5.00 for every share of 2seventy bio they own.
On Monday, Bristol Myers Squibb & Co BMY announced that it will buy 2seventy bio, Inc. TSVT for $5.00 per share in a cash deal, which totals around $286 million in equity value, or about $102 million after accounting for estimated cash.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) has announced a merger agreement where Bristol Myers Squibb (NYSE: BMY) will buy all shares of 2seventy bio for $5.00 each, totaling around $286 million in cash, or $102 million after accounting for estimated cash. This acquisition offers an 88% premium compared to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy made the decision to..."
The most recent time the economy faced two consecutive quarters of negative growth in gross domestic product was in the first and second quarters of 2022. During that period, there was a 1.6% decrease in the first quarter and a 0.6% drop in the second quarter.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AAD--Bristol Myers Squibb has shared new findings from the Phase 3 POETYK PsA-2 Trial, showing that Sotyktu (deucravacitinib) is more effective compared to other treatments.
Bristol Myers Squibb (BMY) finished the last trading session at $60.18, which is an increase of 0.6% compared to the previous day's closing price.
Bristol-Myers Squibb Company (NYSE:BMY) will participate in the 45th Annual TD Cowen Health Care Conference on March 4, 2025, at 2:30 PM ET. Adam Lenkowsky, the Executive Vice President and Chief Commercial Officer, will represent the company. Steve Scala from Cowen will also be part of the conference call.
Evotec has made significant progress in its ongoing partnership with Bristol Myers Squibb, focusing on neurodegeneration research. As a result of their latest achievement, Evotec will receive a payment of $20 million to continue advancing a promising pre-clinical program. This collaboration highlights the commitment of both companies to improve treatments in neuroscience.